Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma
胰腺导管腺癌靶向放射治疗的开发
基本信息
- 批准号:10257694
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-21 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAnimal ModelBiopsyBloodCancer EtiologyCessation of lifeClinicClinicalClinical TrialsConsultationsDevelopmentDiagnosisDiseaseDoseDose-LimitingExternal Beam Radiation TherapyGoalsGrantHumanIn VitroInvestigational DrugsKidneyLabelLaboratoriesLicensureMalignant neoplasm of pancreasMaximum Tolerated DoseMeasuresMedical centerMolecular WeightMonitorNebraskaNeurotensin ReceptorsNew Drug ApprovalsNormal tissue morphologyOperative Surgical ProceduresOutcomePancreatic Ductal AdenocarcinomaPathway interactionsPatient-Focused OutcomesPatientsPeptide HydrolasesPharmaceutical PreparationsPharmacologic SubstancePhasePrognosisRadiation Dose UnitRadiation ToxicityRadiation therapyRadionuclide therapyRadiopharmaceuticalsRadiosensitizationRegimenResidual TumorsRiskSafetySmall Business Technology Transfer ResearchStructureSurvival RateTechnologyTherapeuticTimeToxic effectTreatment EfficacyTreatment ProtocolsTumor TissueTumor VolumeUniversitiesXenograft Modeladductcancer diagnosiscancer therapychemotherapyclinical translationcommercial applicationcommercializationcomparative efficacydosimetryfirst-in-humanimprovedin vivomanufacturing scale-upmouse modelnovelnovel therapeuticsoverexpressionpancreatic ductal adenocarcinoma modelreceptorresidencescale uptargeted agenttargeted radiotherapeutictumoruptake
项目摘要
In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth
leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90%
of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options
are needed to improve the poor prognosis for patients with PDAC. External beam radiation therapy is a staple
in the current treatment of PDAC, but its clinical therapeutic efficacy is limited by unavoidable dose-limiting
toxicities to normal tissues and its inability to target metastatic disease. The development of low-molecular-
weight targeted radionuclide therapeutics (TRTs) is an attractive alternative to external beam radiation therapy
due to their reduced non-target toxicity and systemic targeting capabilities. However, the short residence time of
TRTs in tumors due to clearance greatly reduces deliverable radiation doses and inhibits clinical translation. The
Garrison laboratory at the University of Nebraska Medical Center has developed a novel endolysosomal trapping
approach to substantially increase tumor residualization and radiation dose delivery of receptor-targeted agents.
The neurotensin receptor subtype I (NTSR1) has been shown to be overexpressed in PDAC biopsies and has
been validated in the clinic. Using this trapping approach, the long-term goal of this project is for AdductNE, LLC
to develop an NTSR1-targeted TRT with high therapeutic efficacy for PDAC to improve clinical outcomes.
During this Phase I project, AdductNE, LLC will optimize the structure of the TRT to further enhance the tumor-
to-kidney (T/K) radiation dose ratios (Specific Aim 1) and provide proof-of-concept of its therapeutic efficacy and
safety in PDAC models (Specific Aim 2). In Specific Aim 1, the TRT construct will be altered to increase NTSR1-
positive tumor residualization and reduce/block renal uptake resulting in an increase in T/K ratios. In vitro
characterization of the TRT will be carried out to examine stability, protease inhibition, NTSR1 affinity and adduct
formation efficacy. In vivo tumor targeting and retention efficacy, tumor-to-non-target ratios and human dosimetry
estimates will be determined in PDAC xenograft models. For Specific Aim 2, the maximum tolerated dose,
therapeutic efficacy and safety of the TRT will be established. Histopathological and blood analysis/monitoring
will be carried out to measure radiotoxicity in tumor and normal tissues. In Phase II, AdductNE, LLC will validate
the TRT in more advanced PDAC models and in conjunction with current chemotherapeutic regimens. The
necessary toxicity and manufacturing scale-up studies will also be performed for the submission of an
Investigational New Drug (IND)-approval. In 2018, the market value estimate for pancreatic cancer treatment
was $1.9 billion but is expected to grow to $4.7 billion by 2026. Our commercialization strategy is to develop,
validate and de-risk our drug as we progress towards first-in-human studies. AdductNE, LLC will partner, through
licensure or acquisition, with larger pharmaceutical companies to help support and guide clinical translation.
仅在2020年,胰腺癌估计就导致美国47,050人死亡,使其成为第四大癌症。
癌症相关死亡的主要原因。胰腺导管腺癌(PDAC)占90%以上。
在所有胰腺癌诊断中,胰腺癌的总五年生存率仅为10%。新的治疗选择
以改善PDAC患者的不良预后。体外放射治疗是
但其临床治疗效果受到不可避免的剂量限制,
对正常组织的毒性和不能靶向转移性疾病。低分子-
重量靶向放射性核素治疗(TRT)是一种有吸引力的替代外束放射治疗
这是因为它们降低了非靶毒性和全身靶向能力。然而,短的停留时间
由于清除,肿瘤中的TRT大大减少了可输送的辐射剂量并抑制了临床转化。的
内布拉斯加大学医学中心的加里森实验室开发了一种新的内溶酶体捕获技术,
这是一种基本上增加肿瘤残留和受体靶向剂的辐射剂量递送的方法。
神经降压素受体亚型I(NTSR 1)已被证明在PDAC活检中过表达,
在临床上得到验证。使用这种捕获方法,该项目的长期目标是为AdductNE,LLC
开发NTSR 1靶向TRT,对PDAC具有高疗效,以改善临床结局。
在这个I期项目中,AdductNE,LLC将优化TRT的结构,以进一步增强肿瘤-
与肾脏(T/K)辐射剂量比(具体目标1)并提供其治疗功效的概念验证,
PDAC模型的安全性(具体目标2)。在特定目标1中,TRT构建体将被改变以增加NTSR 1-
阳性肿瘤残留和减少/阻断肾摄取,导致T/K比值增加。体外
将进行TRT的表征以检查稳定性、蛋白酶抑制、NTSR 1亲和力和加合物
形成效能体内肿瘤靶向和保留效力、肿瘤与非靶比和人体剂量测定
将在PDAC异种移植模型中确定估计值。对于特定目标2,最大耐受剂量,
将确定TRT的疗效和安全性。组织学和血液分析/监测
将进行测量肿瘤和正常组织中的放射毒性。在第二阶段,AdductNE,LLC将确认
TRT在更先进的PDAC模型中以及与当前化疗方案联合使用。的
还将进行必要的毒性和生产规模扩大研究,以提交
研究性新药(IND)-批准。2018年,胰腺癌治疗的市场价值估计
19亿美元,但预计到2026年将增长到47亿美元。我们的商业化战略是开发,
在我们进行首次人体研究的过程中,验证我们的药物并降低其风险。AdductNE,LLC将通过
许可证或收购,与大型制药公司合作,以帮助支持和指导临床翻译。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jered C Garrison其他文献
Jered C Garrison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jered C Garrison', 18)}}的其他基金
Development of a Theranostic Nanomedicine Construct for Ovarian Cancer
卵巢癌治疗诊断纳米医学结构的开发
- 批准号:
10218729 - 财政年份:2021
- 资助金额:
$ 40万 - 项目类别:
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer
开发针对结直肠癌的 NTSR1 靶向放射疗法
- 批准号:
10352463 - 财政年份:2021
- 资助金额:
$ 40万 - 项目类别:
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer
开发针对结直肠癌的 NTSR1 靶向放射疗法
- 批准号:
10591477 - 财政年份:2021
- 资助金额:
$ 40万 - 项目类别:
Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer
开发针对结直肠癌的 NTSR1 靶向放射疗法
- 批准号:
10185518 - 财政年份:2021
- 资助金额:
$ 40万 - 项目类别:
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
利用 Hypoxia-S 增强 BB2r 靶向放射治疗前列腺癌
- 批准号:
9069745 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
利用 Hypoxia-S 增强 BB2r 靶向放射治疗前列腺癌
- 批准号:
8845527 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
利用 Hypoxia-S 增强 BB2r 靶向放射治疗前列腺癌
- 批准号:
8697922 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer
缺氧增强铃蟾肽类似物治疗前列腺癌的设计和评价
- 批准号:
8013460 - 财政年份:2010
- 资助金额:
$ 40万 - 项目类别:
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer
缺氧增强铃蟾肽类似物治疗前列腺癌的设计和评价
- 批准号:
8232144 - 财政年份:2010
- 资助金额:
$ 40万 - 项目类别:
Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer
缺氧增强铃蟾肽类似物治疗前列腺癌的设计和评价
- 批准号:
8033262 - 财政年份:2010
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists